NCT06931080

Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Trial to Evaluate the Efficacy and Safety of EB-1020 Once Daily QD XR Capsules Administered Orally at Low or High Dose in Adults With Attention-deficit/Hyperactivity Disorder

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 630 (estimated)
• Sponsor: Otsuka Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.

Conditions

• Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

Type	Name	Description
DRUG	EB-1020 (Centanafadine) 164.4 mg	164.4 mg, capsule, oral, once daily, for 6 weeks
DRUG	EB-1020 (Centanafadine) 328.8 mg	328.8 mg, capsule, oral, once daily, for 6 weeks
DRUG	Placebo	Placebo, capsule, oral, once daily, for 6 weeks

Timeline

• Start date: 2025-04-30
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2025-04-16
• Last updated: 2025-08-03

Locations

1 site across 1 country: Japan